Trial
NCT04335071
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Insel Gruppe AG, University Hospital Bern
Collaborators
Roche Pharma AG
Condition
SARS-CoV-2 Infection
Intervention
Tocilizumab (TCZ)
Why stopped
1.) Not possible to recruit the planned number of patients during the planned study period; 2.) "Dexamethason" was included in the standard of care for the study population during the course of the study and inclusion criteria could no longer be met.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-14